Abstract
Observational studies suggest that mammographic density (MD) may have a role in the unexplained protective effect of childhood adiposity on breast cancer risk. Here, we investigated a complex and interlinked relationship between puberty onset, adiposity, MD, and their effects on breast cancer using Mendelian randomization (MR).
We estimated the effects of childhood and adulthood adiposity, and age at menarche on MD phenotypes (dense area (DA), non-dense area (NDA), percent density (PD)) using MR and multivariable MR (MVMR), allowing us to disentangle their total and direct effects. Next, we examined the effect of MD on breast cancer risk, including risk of molecular subtypes, and accounting for genetic pleiotropy. Finally, we used MVMR to evaluate whether the protective effect of childhood adiposity on breast cancer was mediated by MD.
Childhood adiposity had a strong inverse effect on mammographic DA, while adulthood adiposity increased NDA. Later menarche had an effect of increasing DA and PD, but when accounting for childhood adiposity, this effect attenuated to the null. DA and PD had a risk-increasing effect on breast cancer across all subtypes. The MD single-nucleotide polymorphism (SNP) estimates were extremely heterogeneous, and examination of the SNPs suggested different mechanisms may be linking MD and breast cancer. Finally, MR mediation analysis estimated that 56% (95% CIs [32% - 79%]) of the childhood adiposity effect on breast cancer risk was mediated via DA.
In this work, we sought to disentangle the relationship between factors affecting MD and breast cancer. We showed that higher childhood adiposity decreases mammographic DA, which subsequently leads to reduced breast cancer risk. Understanding this mechanism is of great importance for identifying potential targets of intervention, since advocating weight gain in childhood would not be recommended.
Competing Interest Statement
T.G.R. is employed by GSK outside of this work, for unrelated research. All other authors declare no competing interests.
Funding Statement
M.V. is supported by the University of Bristol Alumni Fund (Professor Sir Eric Thomas Scholarship). B.L.L. is supported by the University of Bristol Vice-Chancellor's fellowship, Academy of Medical Sciences, Elizabeth Blackwell Institute for Health Research (University of Bristol) and the Wellcome Trust Institutional Strategic Support Fund (ISSF3 (204813/Z/16/Z) and AMS (SBF003/1170)). M.V., G.D.S., E.S., T.G.R., R.C.R. work in the UK Medical Research Council Integrative Epidemiology Unit at the University of Bristol supported by Medical Research Council (MC_UU_00032/01, MC_UU_00032/03, MC_UU_00032/04). This work is also supported by a Cancer Research UK programme grant (the Integrative Cancer Epidemiology Programme) (C18281/A29019). W.S., L.A.H., J.H.R., S.E.A are supported by the U.S. National Institutes of Health (R01CA237541, R01CA264987, R01CA166827).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The GWAS data for BCAC 2017 breast cancer (ieu-a-1126, ieu-a-1127, ieu-a-1128) and age at menarche (ukb-b-3768) was accessed from OpenGWAS (https://gwas.mrcieu.ac.uk). The BCAC 2020 molecular subtype data is available at https://bcac.ccge.medschl.cam.ac.uk/bcacdata/ oncoarray/oncoarray-and-combined-summary-result/. Childhood and adult body size GWAS data was published in ref [5]. This study uses data from a GWAS of mammographic density (ref [32]). The RPGEH genotype data are available upon application to the KP Research Bank (https://researchbank.kaiserpermanente.org/). Additional relevant information is available from the authors upon reasonable request.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
